Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Jul 7;118(1):44-9.
doi: 10.1182/blood-2011-02-339275. Epub 2011 May 6.

HIV-associated Hodgkin lymphoma during the first months on combination antiretroviral therapy

Emilie Lanoy  1 , Philip S Rosenberg, Fabien Fily, Anne-Sophie Lascaux, Valerie Martinez, Maria Partisani, Isabelle Poizot-Martin, Elisabeth Rouveix, Eric A Engels, Dominique Costagliola, James J Goedert; FHDH-ANRS CO4
Affiliations

HIV-associated Hodgkin lymphoma during the first months on combination antiretroviral therapy

Emilie Lanoy et al. Blood. .

Abstract

Hodgkin lymphoma (HL) incidence with HIV infection may have increased with the introduction of combination antiretroviral therapy (cART), suggesting that immune reconstitution may contribute to some cases. We evaluated HL risk with cART during the first months of treatment. With 187 HL cases among 64 368 HIV patients in France, relative rates (RRs) and 95% confidence intervals (CIs) of HL were estimated using Poisson models for duration of cART, CD4 count, and HIV load, with and without adjustment for demographic/clinical covariates. HL risk was unrelated to cART use overall, but it was related to time intervals after cART initiation (P = .006). Risk was especially and significantly elevated in months 1-3 on cART (RR 2.95, CI 1.64-5.31), lower in months 4-6 (RR 1.63), and null with longer use (RR 1.00). CD4 count was strongly associated with HL risk (P < 10⁻⁶), with the highest HL incidence at 50-99 CD4 cells/mm³. With adjustment for CD4 count and covariates, HL risk was elevated, but not significantly (RR 1.42), in months 1-3 on cART. HIV load had no added effect. HL risk increased significantly soon after cART initiation, which was largely explained by the CD4 count. Further studies of HIV-associated HL are needed.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Relative risk of HL. Risk was obtained by last CD4 cell count before diagnosis and was adjusted for age, sex and exposure group, migration from sub-Saharan Africa, AIDS stage, and cART use and duration (Table 2 Model 3).
See this image and copyright information in PMC

References

    1. Engels EA, Pfeiffer RM, Goedert JJ, et al. Trends in cancer risk among people with AIDS in the United States 1980-2002. AIDS. 2006;20(12):1645–1654. - PubMed
    1. Herida M, Mary-Krause M, Kaphan R, et al. Incidence of non-AIDS-defining cancers before and during the highly active antiretroviral therapy era in a cohort of human immunodeficiency virus-infected patients. J Clin Oncol. 2003;21(18):3447–3453. - PubMed
    1. Goedert JJ, Cote TR, Virgo P, et al. Spectrum of AIDS-associated malignant disorders. Lancet. 1998;351(9119):1833–1839. - PubMed
    1. Biggar RJ, Jaffe ES, Goedert JJ, Chaturvedi A, Pfeiffer R, Engels EA. Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDS. Blood. 2006;108(12):3786–3791. - PMC - PubMed
    1. Powles T, Robinson D, Stebbing J, et al. Highly active antiretroviral therapy and the incidence of non-AIDS-defining cancers in people with HIV infection. J Clin Oncol. 2009;27(6):884–890. - PubMed

Publication types

MeSH terms

Substances